Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

12.79
+4.3451.36%
Volume:1.44M
Turnover:16.97M
Market Cap:21.37M
PE:-1.03
High:14.42
Open:8.29
Low:8.11
Close:8.45
52wk High:29.00
52wk Low:2.86
Shares:1.67M
Float Shares:1.48M
Volume Ratio:0.21
T/O Rate:97.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.3849
EPS(LYR):-12.3849
ROE:-3891.64%
ROA:-64.28%
PB:-3.96
PE(LYR):-1.03

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet

Reuters
·
Nov 20

BUZZ-Microcap Kazia shares soar 40% after positive drug update on single-patient treatment

Reuters
·
Nov 20

What Sparked Kazia Therapeutics' Over 51% After-Hours Surge?

Benzinga_recent_news
·
Nov 19

Kazia Therapeutics Reports Initial iCR in Metastatic TNBC and Advances Pipeline Programs

Reuters
·
Nov 19

Kazia Therapeutics reports A$42,000 revenue for fiscal year 2025

Reuters
·
Nov 08

Kazia Therapeutics Delays Annual Financial Report Filing

Reuters
·
Nov 01

BRIEF-Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner

Reuters
·
Oct 27

Kazia Therapeutics Ltd - Seeks FDA Feedback on Regulatory Pathway Under Project Frontrunner for Paxalisib

THOMSON REUTERS
·
Oct 27

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential Nda Filing in Alignment With FDA Initiative Project Frontrunner

THOMSON REUTERS
·
Oct 27

Kazia Therapeutics Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for Cancer Treatment

Reuters
·
Oct 08

BRIEF-Kazia Therapeutics Announces Collaboration And In-Licensing Agreement For First-In-Class PD-L1 Protein Degrader Program

Reuters
·
Oct 07

Kazia Therapeutics signs collaboration and in-licensing agreement for PD-L1

TIPRANKS
·
Oct 07

Kazia Therapeutics Announces Collaboration and in-Licensing Agreement for First-in-Class Pd-L1 Protein Degrader Program

THOMSON REUTERS
·
Oct 07

Kazia Therapeutics Ltd - to Make $1.39 Mln Payment Under Agreement

THOMSON REUTERS
·
Oct 07

Kazia Therapeutics Ltd: Announces 86% Tumor Reduction in Tnbc Patient Treated With Paxalisib-Immunotherapy Regimen

THOMSON REUTERS
·
Oct 02

Kazia Therapeutics Ltd - Imaging Shows 86% Tumor Reduction After Three Weeks of Therapy

THOMSON REUTERS
·
Oct 02

Kazia Therapeutics Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient

Reuters
·
Oct 02

Kazia Therapeutics Ltd : Maxim Group Raises Target Price to $20 From $15

THOMSON REUTERS
·
Oct 02

Kazia Therapeutics Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers

Reuters
·
Oct 01

Kazia Therapeutics Shares up 56% Premarket After Co's Breast Cancer Therapy Disrupts Tumor Cell Clusters

THOMSON REUTERS
·
Sep 11